IPCALAB.NS Cash Flow
Ipca Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:31
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹8.06 Bn | ₹9.45 Bn | ₹13.21 Bn | ₹11.42 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-7.25 Bn | ₹-12.92 Bn | ₹-8.70 Bn | ₹-2.47 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹5.07 Bn | ₹-5.53 Bn | ₹-2.83 Bn | ₹-7.54 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹5.88 Bn | ₹-9.00 Bn | ₹1.69 Bn | ₹1.42 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹9.91 Bn | ₹16.55 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from IPCALAB.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).